Project Grant R41AI184019
Award Date
8/1/24
Completion Date
7/31/26
Dollars Obligated
$300K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Buffalo, NY 14228, USA
Similar Awards
This Project Grant award of $449,787 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research focused on understanding mucosal immunity and host defense against vaginal candidiasis, a common fungal infection caused by Candida albicans. The research aims to elucidate the role of the Th17 cell/IL-17 pathway in controlling this mucosal infection, which has implications for developing better...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $642,775 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of California, Davis to accelerate the discovery of new antifungal peptides using one-bead one-compound (OBOC) combinatorial technology. The research aims to rapidly develop and optimize novel broad-spectrum antifungal agents with defined physicochemical properties, diverse mechanisms of action, and a high...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $170,000.00 to Prokaryotics Incorporated to support research and development of a novel antifungal agent that inhibits the glycosylphosphatidylinositol (GPI) biosynthesis pathway in fungal pathogens.
The key goals of this 2-year project are to: 1) Perform cryo-EM structural studies to elucidate the molecular interactions between the lead...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $300,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Microrid Technologies Inc. located in Dix Hills, NY. The goal of this 1-year project is to discover and develop new antifungal therapeutics that target the fungal enzyme ceramide synthase 1 (CER1), which is essential for fungal growth and survival in host environments. The researchers will screen compound libraries to...
This $175,500 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to develop an engineered probiotic yeast therapy for treating Candida albicans biofilm infections in the gut. The research team at North Carolina State University will create strains of the probiotic yeast Saccharomyces boulardii that can detect and bind to C. albicans biofilms, then secrete proteins to inhibit biofilm...
This $837,644 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to develop novel vaccines targeting the virulence factor PNAG (poly-beta-(1,6)-N-acetylglucosamine) for preventing antimicrobial-resistant infections. The grant funds an interdisciplinary research effort to establish new methods for synthesizing a comprehensive library of PNAG glycans with varied amine/acetylation patterns, conjugate...
This $134,800 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research by Dr. Shakti Singh at the Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center. The project aims to study the role of Hyr1/Iff-like proteins in the virulence of the multi-drug resistant fungal pathogen Candida auris, and to evaluate their potential as vaccine targets using an mRNA platform and animal...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to advance the development of natural phenolic compounds, specifically caffeic acid phenethyl ester (CAPE) and ellagic acid (EA), for the management of oral candidiasis. The $416,396 award supports a 5-year research project led by Dr. Eleftherios Mylonakis at The Methodist Hospital Research Institute. The key objectives...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $300,000 to support the preclinical development of occidiofungin, a novel antifungal compound, for the treatment of oral and dermal candidiasis.
The key objectives are to establish an effective formulation for occidiofungin and conduct the necessary toxicological and stability studies to support an Investigational...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to develop a cell-based therapy to treat systemic Candida infections in immunocompromised patients. The $251,250 award to The University of Texas MD Anderson Cancer Center will fund research to generate chimeric antigen receptor (CAR) constructs and express them in T cells and macrophages to target and clear Candida infections without disrupting...